Your browser doesn't support javascript.
Reduced B cell antigenicity of Omicron lowers host serologic response.
Tubiana, Jérôme; Xiang, Yufei; Fan, Li; Wolfson, Haim J; Chen, Kong; Schneidman-Duhovny, Dina; Shi, Yi.
  • Tubiana J; Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv 6997801, Israel; School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.
  • Xiang Y; Center for Protein Engineering and Therapeutics, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Fan L; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Wolfson HJ; Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Chen K; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. Electronic address: koc5@pitt.edu.
  • Schneidman-Duhovny D; School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel. Electronic address: dina.schneidman@mail.huji.ac.il.
  • Shi Y; Center for Protein Engineering and Therapeutics, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: wally.yis@gmail.com.
Cell Rep ; 41(3): 111512, 2022 10 18.
Article in English | MEDLINE | ID: covidwho-2060516
ABSTRACT
The SARS-CoV-2 Omicron variant evades most neutralizing vaccine-induced antibodies and is associated with lower antibody titers upon breakthrough infections than previous variants. However, the mechanism remains unclear. Here, we find using a geometric deep-learning model that Omicron's extensively mutated receptor binding site (RBS) features reduced antigenicity compared with previous variants. Mice immunization experiments with different recombinant receptor binding domain (RBD) variants confirm that the serological response to Omicron is drastically attenuated and less potent. Analyses of serum cross-reactivity and competitive ELISA reveal a reduction in antibody response across both variable and conserved RBD epitopes. Computational modeling confirms that the RBS has a potential for further antigenicity reduction while retaining efficient receptor binding. Finally, we find a similar trend of antigenicity reduction over decades for hCoV229E, a common cold coronavirus. Thus, our study explains the reduced antibody titers associated with Omicron infection and reveals a possible trajectory of future viral evolution.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.111512

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.111512